Amgen prostate cancer：Prostate Cancer Disease State Education Deck
Prostate Cancer Disease State Education Deck
*AmgenisinvestigatinganumberofT-cellengagingplatforms,including...mCRPC,metastaticcastration-resistantprostatecancer;PSMA,prostate-specific ...。其他文章還包含有：「TargetingProstate」、「TargetingSTEAP1」、「Amgenstopscancertrial」、「AmgenAxesProstateCancerDrug」、「AMGENTOPRESENTNEWRESEARCHFROM...」、「Amgencutsprostatecancerdrugin$650Mwritedown...」、「AMGENPRESENTSNEWTARLATAMABCLINICALDAT...
查看更多 離開網站
Targeting Prostate
https://www.amgenoncology.com
Therefore, PSMA is an attractive target for the treatment of prostate cancer and potentially other solid tumors.2-4. Learn more about modalities targeting PSMA:
Targeting STEAP1
https://www.amgenoncology.com
Discover why STEAP1 (six-transmembrane epithelial antigen of prostate 1) is a therapeutic target and overexpressed in prostate cancer.
Amgen stops cancer trial
https://www.fiercebiotech.com
Amgen is testing tarlatamab in a form of prostate cancer and has another mCRPC project on the go. ... AmgenTeneobiobispecific antibodiesprostate ...
Amgen Axes Prostate Cancer Drug
https://www.biospace.com
The prostate cancer drug was acquired as part of a $900 million upfront buy of Teneobio in 2021. In its reprioritization decision, Amgen said it ...
AMGEN TO PRESENT NEW RESEARCH FROM ...
https://www.prnewswire.com
These results further justify exploration of this modality as a potential therapy for prostate cancer. Dose expansion and optimization are ...
Amgen cuts prostate cancer drug in $650M writedown ...
https://endpts.com
Amgen discontinues prostate cancer drug in $650M writedown, as obesity pipeline comes into focus in 2024. Andrew Dunn. Biopharma Correspondent.
AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA ...
https://www.amgen.com
Phase 1 Tarlatamab Study Showed Encouraging Antitumor Activity With Median Duration of Response of 13 Months in Small Cell Lung Cancer.
Three Things to Look Forward to at #ESMO23
https://www.amgen.com
New data underscore the potential of Amgen's precision medicine candidates for patients facing high unmet needs in cancer ... prostate cancer ( ...
The PSMA
https://pubmed.ncbi.nlm.nih.go
Results: AMG 160 induces potent, specific killing of PSMA-expressing prostate cancer cell lines in vitro, with half-maximal lysis of 6-42 pmol/L ...